Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols
  • Central Nervous System Neoplasms
  • Lymphoma, Large B-Cell, Diffuse

abstract

  • Given the overall low rate of CNS recurrence and lack of prophylaxis-associated survival benefit, the current data called into question the practice of CNS prophylaxis in the rituximab era.

publication date

  • June 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.26588

PubMed ID

  • 22006274

Additional Document Info

start page

  • 2944

end page

  • 51

volume

  • 118

number

  • 11